Trial Profile
A Multicenter, Partially-Blinded, Randomized, 24-Week, Parallel-Group, Non-Inferiority, Open-Label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate; Tiotropium bromide
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ARGON
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 24 Jan 2022 A review outlining the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches comprising data from 3 study (QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF) published in the Advances in Therapy
- 28 Jan 2021 Results of a meta-analysis from following phase III studies: NCT02924688, NCT02571777, NCT03158311, NCT02676076 and NCT02676089 published in the European Respiratory Journal
- 27 Jan 2021 Results of a pooled analysis assessing cardiovascular safety from four clinical studies: PALLADIUM, IRIDIUM, ARGON and QUARTZ published in the Respiratory Medicine